Preclinical evaluation of the AKT inhibitor MK-2206 in nasopharyngeal carcinoma cell lines
- Author
- MA, Brigette B. Y1 ; LUI, Vivian W. Y2 ; HUI, Connie W. C1 ; LAU, Cecilia P. Y1 ; WONG, Chi-Hang1 ; HUI, Edwin P1 ; NG, Margaret H3 ; TSAO, S. W4 ; YAN LI5 ; CHAN, Anthony T. C1
[1] State Key Laboratory in Oncology in South China, Sir Y.K. Pao Centre for Cancer, Department of Clinical Oncology, Cancer Drug Testing Unit, Hong Kong Cancer Institute and Li Ka Shing Institute of Health Sciences, Chinese University of Hong Kong, Shatin, Hong-Kong
[2] Department of Otolaryngology, University of Pittsburgh, Pittsburgh, PA, United States
[3] Department of Anatomical and Cellular Pathology, Chinese University of Hong Kong, Shatin, Hong-Kong
[4] Department of Anatomy, University of Hong Kong, Pokfulam, Hong-Kong
[5] Infectious Disease, Oncology, Respiratory & Immunology Clinical Development, Merck Sharp and Dohme Corp, Inc, North Wales, PA, United States - Source
Investigational new drugs. 2013, Vol 31, Num 3, pp 567-575, 9 p ; ref : 29 ref
- CODEN
- INNDDK
- ISSN
- 0167-6997
- Scientific domain
- Medical oncology; Pharmacology drugs
- Publisher
- Springer, New York, NY
- Publication country
- United States
- Document type
- Article
- Language
- English
- Author keyword
- AKT MAPK MK-2206 Nasopharyngeal cancer
- Keyword (fr)
- Akt protein kinase Cancer du nasopharynx Carcinome du nasopharynx Essai préclinique Evaluation In vitro Lignée cellulaire établie Mitogen-activated protein kinase Mécanisme action Inhibiteur AKT Cancer Enzyme Pathologie ORL Pathologie du pharynx Transferases Tumeur maligne
- Keyword (en)
- Akt protein kinase Nasopharynx cancer Nasopharynx carcinoma Preclinical trial Evaluation In vitro Established cell line Mitogen-activated protein kinase Mechanism of action AKT inhibitor Cancer Enzyme ENT disease Pharynx disease Transferases Malignant tumor
- Keyword (es)
- Akt protein kinase Cáncer del nasopharynx Carcinoma nasofaringe Ensayo preclínico Evaluación In vitro Línea celular establecida Mitogen-activated protein kinase Mecanismo acción Inhibidor AKT Cáncer Enzima ORL patología Faringe patología Transferases Tumor maligno
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B02 Pharmacology. Drug treatments / 002B02R Antineoplastic agents / 002B02R01 General aspects
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B04 Tumors / 002B04C Multiple tumors. Solid tumors. Tumors in childhood (general aspects)
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B10 Otorhinolaryngology. Stomatology / 002B10B Upper respiratory tract, upper alimentary tract, paranasal sinuses, salivary glands: diseases, semeiology / 002B10B01 Tumors
- Discipline
- Otorhinolaryngology. Stomatology Pharmacological treatments Tumours
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 27435288
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Access to the document
Install on your browser
DOI
10.1007/s10637-012-9896-5 
https://dx.doi.org/10.1007/s10637-012-9896-5
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:25:\"10.1007\/s10637-012-9896-5\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:90:\"Preclinical evaluation of the AKT inhibitor MK-2206 in nasopharyngeal carcinoma cell lines\";s:9:\"\u0000*\u0000jtitle\";s:25:\"Investigational new drugs\";s:9:\"\u0000*\u0000stitle\";s:17:\"Invest. new drugs\";s:7:\"\u0000*\u0000date\";s:4:\"2013\";s:9:\"\u0000*\u0000volume\";s:2:\"31\";s:8:\"\u0000*\u0000issue\";s:1:\"3\";s:8:\"\u0000*\u0000spage\";s:3:\"567\";s:8:\"\u0000*\u0000epage\";s:3:\"575\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0167-6997\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:2:\"MA\";s:10:\"\u0000*\u0000aufirst\";s:13:\"Brigette B. Y\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:9:{i:0;s:16:\"LUI, Vivian W. Y\";i:1;s:16:\"HUI, Connie W. C\";i:2;s:17:\"LAU, Cecilia P. Y\";i:3;s:14:\"WONG, Chi-Hang\";i:4;s:12:\"HUI, Edwin P\";i:5;s:14:\"NG, Margaret H\";i:6;s:10:\"TSAO, S. W\";i:7;s:6:\"YAN LI\";i:8;s:18:\"CHAN, Anthony T. C\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"INNDDK\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:90:\"Preclinical evaluation of the AKT inhibitor MK-2206 in nasopharyngeal carcinoma cell lines\";s:8:\"\u0000*\u0000place\";s:12:\"New York, NY\";s:6:\"\u0000*\u0000pub\";s:8:\"Springer\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"9\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:25:\"10.1007\/s10637-012-9896-5\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:90:\"Preclinical evaluation of the AKT inhibitor MK-2206 in nasopharyngeal carcinoma cell lines\";s:9:\"\u0000*\u0000jtitle\";s:25:\"Investigational new drugs\";s:9:\"\u0000*\u0000stitle\";s:17:\"Invest. new drugs\";s:7:\"\u0000*\u0000date\";s:4:\"2013\";s:9:\"\u0000*\u0000volume\";s:2:\"31\";s:8:\"\u0000*\u0000issue\";s:1:\"3\";s:8:\"\u0000*\u0000spage\";s:3:\"567\";s:8:\"\u0000*\u0000epage\";s:3:\"575\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0167-6997\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:2:\"MA\";s:10:\"\u0000*\u0000aufirst\";s:13:\"Brigette B. Y\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:9:{i:0;s:16:\"LUI, Vivian W. Y\";i:1;s:16:\"HUI, Connie W. C\";i:2;s:17:\"LAU, Cecilia P. Y\";i:3;s:14:\"WONG, Chi-Hang\";i:4;s:12:\"HUI, Edwin P\";i:5;s:14:\"NG, Margaret H\";i:6;s:10:\"TSAO, S. W\";i:7;s:6:\"YAN LI\";i:8;s:18:\"CHAN, Anthony T. C\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"INNDDK\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:90:\"Preclinical evaluation of the AKT inhibitor MK-2206 in nasopharyngeal carcinoma cell lines\";s:8:\"\u0000*\u0000place\";s:12:\"New York, NY\";s:6:\"\u0000*\u0000pub\";s:8:\"Springer\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"9\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"UnpaywallOpenUrl\":35:{s:8:\"\u0000*\u0000email\";s:27:\"assistance-portail@inist.fr\";s:6:\"\u0000*\u0000fmt\";N;s:6:\"\u0000*\u0000doi\";s:25:\"10.1007\/s10637-012-9896-5\";s:6:\"\u0000*\u0000pii\";N;s:7:\"\u0000*\u0000pmid\";N;s:9:\"\u0000*\u0000atitle\";N;s:9:\"\u0000*\u0000jtitle\";N;s:9:\"\u0000*\u0000stitle\";N;s:7:\"\u0000*\u0000date\";N;s:9:\"\u0000*\u0000volume\";N;s:8:\"\u0000*\u0000issue\";N;s:8:\"\u0000*\u0000spage\";N;s:8:\"\u0000*\u0000epage\";N;s:8:\"\u0000*\u0000pages\";N;s:7:\"\u0000*\u0000issn\";N;s:8:\"\u0000*\u0000eissn\";N;s:9:\"\u0000*\u0000aulast\";N;s:10:\"\u0000*\u0000aufirst\";N;s:9:\"\u0000*\u0000auinit\";N;s:10:\"\u0000*\u0000auinitm\";N;s:5:\"\u0000*\u0000au\";N;s:9:\"\u0000*\u0000aucorp\";N;s:7:\"\u0000*\u0000isbn\";N;s:8:\"\u0000*\u0000coden\";N;s:8:\"\u0000*\u0000genre\";N;s:7:\"\u0000*\u0000part\";N;s:9:\"\u0000*\u0000btitle\";N;s:8:\"\u0000*\u0000title\";N;s:8:\"\u0000*\u0000place\";N;s:6:\"\u0000*\u0000pub\";N;s:10:\"\u0000*\u0000edition\";N;s:9:\"\u0000*\u0000tpages\";N;s:9:\"\u0000*\u0000series\";N;s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";N;}"
Unpaywall access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:25:\"10.1007\/s10637-012-9896-5\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:90:\"Preclinical evaluation of the AKT inhibitor MK-2206 in nasopharyngeal carcinoma cell lines\";s:9:\"\u0000*\u0000jtitle\";s:25:\"Investigational new drugs\";s:9:\"\u0000*\u0000stitle\";s:17:\"Invest. new drugs\";s:7:\"\u0000*\u0000date\";s:4:\"2013\";s:9:\"\u0000*\u0000volume\";s:2:\"31\";s:8:\"\u0000*\u0000issue\";s:1:\"3\";s:8:\"\u0000*\u0000spage\";s:3:\"567\";s:8:\"\u0000*\u0000epage\";s:3:\"575\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0167-6997\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:2:\"MA\";s:10:\"\u0000*\u0000aufirst\";s:13:\"Brigette B. Y\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:9:{i:0;s:16:\"LUI, Vivian W. Y\";i:1;s:16:\"HUI, Connie W. C\";i:2;s:17:\"LAU, Cecilia P. Y\";i:3;s:14:\"WONG, Chi-Hang\";i:4;s:12:\"HUI, Edwin P\";i:5;s:14:\"NG, Margaret H\";i:6;s:10:\"TSAO, S. W\";i:7;s:6:\"YAN LI\";i:8;s:18:\"CHAN, Anthony T. C\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"INNDDK\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:90:\"Preclinical evaluation of the AKT inhibitor MK-2206 in nasopharyngeal carcinoma cell lines\";s:8:\"\u0000*\u0000place\";s:12:\"New York, NY\";s:6:\"\u0000*\u0000pub\";s:8:\"Springer\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"9\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:25:\"10.1007\/s10637-012-9896-5\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:90:\"Preclinical evaluation of the AKT inhibitor MK-2206 in nasopharyngeal carcinoma cell lines\";s:9:\"\u0000*\u0000jtitle\";s:25:\"Investigational new drugs\";s:9:\"\u0000*\u0000stitle\";s:17:\"Invest. new drugs\";s:7:\"\u0000*\u0000date\";s:4:\"2013\";s:9:\"\u0000*\u0000volume\";s:2:\"31\";s:8:\"\u0000*\u0000issue\";s:1:\"3\";s:8:\"\u0000*\u0000spage\";s:3:\"567\";s:8:\"\u0000*\u0000epage\";s:3:\"575\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0167-6997\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:2:\"MA\";s:10:\"\u0000*\u0000aufirst\";s:13:\"Brigette B. Y\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:9:{i:0;s:16:\"LUI, Vivian W. Y\";i:1;s:16:\"HUI, Connie W. C\";i:2;s:17:\"LAU, Cecilia P. Y\";i:3;s:14:\"WONG, Chi-Hang\";i:4;s:12:\"HUI, Edwin P\";i:5;s:14:\"NG, Margaret H\";i:6;s:10:\"TSAO, S. W\";i:7;s:6:\"YAN LI\";i:8;s:18:\"CHAN, Anthony T. C\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"INNDDK\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:90:\"Preclinical evaluation of the AKT inhibitor MK-2206 in nasopharyngeal carcinoma cell lines\";s:8:\"\u0000*\u0000place\";s:12:\"New York, NY\";s:6:\"\u0000*\u0000pub\";s:8:\"Springer\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"9\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:25:\"10.1007\/s10637-012-9896-5\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:90:\"Preclinical evaluation of the AKT inhibitor MK-2206 in nasopharyngeal carcinoma cell lines\";s:9:\"\u0000*\u0000jtitle\";s:25:\"Investigational new drugs\";s:9:\"\u0000*\u0000stitle\";s:17:\"Invest. new drugs\";s:7:\"\u0000*\u0000date\";s:4:\"2013\";s:9:\"\u0000*\u0000volume\";s:2:\"31\";s:8:\"\u0000*\u0000issue\";s:1:\"3\";s:8:\"\u0000*\u0000spage\";s:3:\"567\";s:8:\"\u0000*\u0000epage\";s:3:\"575\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0167-6997\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:2:\"MA\";s:10:\"\u0000*\u0000aufirst\";s:13:\"Brigette B. Y\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:9:{i:0;s:16:\"LUI, Vivian W. Y\";i:1;s:16:\"HUI, Connie W. C\";i:2;s:17:\"LAU, Cecilia P. Y\";i:3;s:14:\"WONG, Chi-Hang\";i:4;s:12:\"HUI, Edwin P\";i:5;s:14:\"NG, Margaret H\";i:6;s:10:\"TSAO, S. W\";i:7;s:6:\"YAN LI\";i:8;s:18:\"CHAN, Anthony T. C\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"INNDDK\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:90:\"Preclinical evaluation of the AKT inhibitor MK-2206 in nasopharyngeal carcinoma cell lines\";s:8:\"\u0000*\u0000place\";s:12:\"New York, NY\";s:6:\"\u0000*\u0000pub\";s:8:\"Springer\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"9\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
